生華生物科技股份有限公司 Approved
最後更新時間 2025/05/15 , 03:30 AM
最後更新時間 2025/05/15 , 03:30 AM
負責人
Hu,Ding-Wu
統一編號
54021973
成立日期
2012/11/16
資本額
NT$1,500,000,000
實收資本額
NT$897,036,200
股票代號
6492
電話
02-89131956
地址
10F, No. 225, Sec. 3, Beisin Rd., Xindian Dist., New Taipei City, 231, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Hu,Ding-Wu Chairman 2.03%
Feng,Yu-Lian Director 4.89% DING LI DEVELOPMENT LTD.
Chen,Jian-Fu Director 1.39% CHUAN PU INVESTMENT HOLDINGS CO., LTD.
Ma,Hai-Yi Director 0.00%
Zhang,Yu-Zhi Independent Director 0.00%
Li,Dong-Yang Independent Director 0.00%
Ma,Yong-Lin Independent Director 0.00%
營業項目
  • Wholesale of Cosmetics(457299)
  • Manufacture of Cosmetics(193299)
  • Wholesale on a Fee or Contract Basis(451099)
  • 公司歷程
  • Change Capital to 1,500,000,000
    2019/08/14
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 250 1,000 1,000
    Operating cost 104 523 448
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 146 477 552
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 146 477 552
    Operating expenses 65,052 306,668 311,663
    Other gain (loss), net - - -
    Operating profit (loss) -64,906 -306,191 -311,111
    Non-operating income and expenses 3,534 13,727 16,066
    Net profit (loss) before tax -61,372 -292,464 -295,045
    Income tax expense (benefits) -3 1,281 1,261
    Net profit (loss) of ongoing business for the current period -61,369 -293,745 -296,306
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -61,369 -293,745 -296,306
    Other comprehensive profit (loss), net 778 3,621 144
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -60,591 -290,124 -296,162
    Net profit (loss) attributable to owners of parent company -61,369 -293,745 -296,306
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company -60,591 -290,124 -296,162
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 -3 -3
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -66,413 -294,219 -286,354
    Net cash inflows (outflows) from investing activities 1,633 6,705 -5,256
    Net cash inflow (outflow) from financing activities -2,401 -8,725 -8,828
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 709 3,401 109
    Increase (decrease) in cash and cash equivalents in the current period -66,472 -292,838 -300,329
    Beginning balance of cash and cash equivalents 1,025,970 1,318,808 1,619,137
    Ending balance of cash and cash equivalents 959,498 1,025,970 1,318,808
    項目 2025 2024 2023
    Current asset 967,598 1,034,839 1,346,575
    Non-current asset 27,779 31,118 16,756
    Total asset 995,377 1,065,957 1,363,331
    Current liability 22,207 31,088 42,888
    Non-current liability 6,729 7,837 3,287
    Total liability 28,936 38,925 46,175
    share capital 897,036 897,436 897,436
    Equity - secruity token - - -
    capital reserve 469,372 469,577 765,883
    retained earning -356,624 -293,874 -296,306
    Other equity 6,018 5,240 1,490
    Treasury stock -49,361 -51,347 -51,347
    Total equity attributable to owners of parent company 966,441 1,027,032 1,317,156
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 966,441 1,027,032 1,317,156
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 518,000 558,000 558,000
    Net asset value per share 10 11 14
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    存款不足之退票事宜
    時間 金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • Senhwa BIOSCIENCES
  • 生華生物科技SENHWA BIOSCIENCES
  • 生華生物科技股份有限公司標章
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Confirmation of employment relationship, etc.
    2021, 2023
  • Confirmation of employment relationship, etc.
    2021
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。